What GLP-1 drugs actually do, from a rheumatologist with an immunology PhD
Dr. Diana Girnita, MD, PhD — Double board-certified rheumatologist; PhD in immunology; founder of Rheumatologist OnCall
Made by Dr. Diana Girnita, MD, PhD · Dr. Diana Girnita — Rheumatologist OnCall · May 1, 2026. Their work, their channel, their words — we are only the signpost. Plays from YouTube; nothing is requested from them until you press play.
GLP-1 drugs are the most talked-about molecules in this space and the most confidently discussed by people who have not read the trials. Here is a rheumatologist with an immunology doctorate going through what is actually established, in twenty-four minutes, without a product to sell at the end.
Worth watching next to the argument on the other side. Dr. Jason Schuster's critique of the same drug class is a different reading of the same evidence, and we have published it — as his opinion, with a balance box, because that is the only honest way to publish a contrarian clinical view.
What to watch for
Which claims she attaches to a trial and which she attaches to mechanism. She is unusually explicit about the difference.
What she says is not known. The list of open questions is longer than the marketing on either side admits.
Watched it, and have a question the video did not settle?
Leave a name and the best way to reach you, and a person on our team follows up. We will not advise on dosing or on whether something is right for you — that is a conversation for a clinician.
